INS and obesity disorder: Recent studies have demonstrated that intravenous, subcutaneous, or intraperitoneal injections with antimiR-34a, antagomiR-132, LNA-29, and LNA-181a antimiRs reduce blood glucose levels, decrease inflammation, improve insulin secretion and its hepatic sensitivity in a mouse model of obesity [306,307,308,309].